 Daniel Merrick
Concepts (305)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 40 | 2023 | 2207 | 3.130 |
Why?
| | Precancerous Conditions | 10 | 2023 | 156 | 2.220 |
Why?
| | Carcinoma, Squamous Cell | 14 | 2023 | 577 | 1.950 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 13 | 2023 | 963 | 1.460 |
Why?
| | Adenocarcinoma | 7 | 2019 | 799 | 0.700 |
Why?
| | Bronchi | 6 | 2018 | 250 | 0.500 |
Why?
| | Chemoprevention | 4 | 2019 | 88 | 0.470 |
Why?
| | Biopsy | 8 | 2023 | 1056 | 0.440 |
Why?
| | Disease Progression | 7 | 2019 | 2418 | 0.440 |
Why?
| | Biomarkers, Tumor | 8 | 2018 | 1048 | 0.430 |
Why?
| | ErbB Receptors | 6 | 2023 | 557 | 0.430 |
Why?
| | Carmustine | 3 | 2020 | 47 | 0.410 |
Why?
| | Heat-Shock Proteins | 1 | 2012 | 113 | 0.390 |
Why?
| | Neovascularization, Pathologic | 5 | 2015 | 283 | 0.390 |
Why?
| | Bronchial Neoplasms | 2 | 2011 | 14 | 0.370 |
Why?
| | Papillomaviridae | 4 | 1996 | 100 | 0.360 |
Why?
| | Lung Diseases | 1 | 2015 | 710 | 0.330 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 621 | 0.330 |
Why?
| | Smoke | 3 | 2020 | 133 | 0.330 |
Why?
| | Keratinocytes | 4 | 1996 | 215 | 0.320 |
Why?
| | Proto-Oncogene Proteins | 3 | 2018 | 609 | 0.320 |
Why?
| | Smoking | 6 | 2019 | 1457 | 0.310 |
Why?
| | Gene Dosage | 3 | 2016 | 129 | 0.300 |
Why?
| | Inflammation | 1 | 2018 | 2499 | 0.300 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2018 | 1147 | 0.300 |
Why?
| | Carcinogenesis | 2 | 2020 | 178 | 0.300 |
Why?
| | B7-H1 Antigen | 2 | 2019 | 139 | 0.290 |
Why?
| | Epoprostenol | 2 | 2018 | 133 | 0.280 |
Why?
| | Iloprost | 4 | 2018 | 46 | 0.270 |
Why?
| | Carcinogens | 5 | 2018 | 105 | 0.270 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2023 | 314 | 0.270 |
Why?
| | Mice | 21 | 2023 | 15052 | 0.250 |
Why?
| | Mutation | 6 | 2023 | 3364 | 0.250 |
Why?
| | In Situ Hybridization, Fluorescence | 3 | 2018 | 310 | 0.240 |
Why?
| | Humans | 49 | 2023 | 115587 | 0.240 |
Why?
| | Sputum | 4 | 2019 | 290 | 0.230 |
Why?
| | Receptor, ErbB-2 | 1 | 2006 | 302 | 0.230 |
Why?
| | Immunohistochemistry | 5 | 2015 | 1642 | 0.230 |
Why?
| | Cardiomyopathy, Hypertrophic, Familial | 1 | 2003 | 16 | 0.220 |
Why?
| | Lung | 9 | 2023 | 3672 | 0.220 |
Why?
| | Neoplasm Invasiveness | 4 | 2015 | 445 | 0.220 |
Why?
| | Chest Pain | 1 | 2003 | 82 | 0.220 |
Why?
| | Cell Proliferation | 4 | 2018 | 2194 | 0.210 |
Why?
| | Desmoglein 3 | 2 | 2022 | 17 | 0.210 |
Why?
| | Epithelial-Mesenchymal Transition | 3 | 2022 | 167 | 0.210 |
Why?
| | Lidocaine | 1 | 2022 | 42 | 0.210 |
Why?
| | Gelatin | 1 | 2022 | 36 | 0.210 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2005 | 503 | 0.200 |
Why?
| | Female | 29 | 2022 | 59913 | 0.200 |
Why?
| | Neuropilin-1 | 1 | 2021 | 9 | 0.200 |
Why?
| | Middle Aged | 18 | 2020 | 26999 | 0.200 |
Why?
| | Male | 28 | 2020 | 55949 | 0.200 |
Why?
| | Ki-67 Antigen | 2 | 2015 | 104 | 0.190 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 2 | 2012 | 88 | 0.190 |
Why?
| | Aged | 13 | 2019 | 19251 | 0.190 |
Why?
| | Air Pollution | 1 | 2023 | 172 | 0.180 |
Why?
| | Cysts | 1 | 2021 | 93 | 0.180 |
Why?
| | Disease Models, Animal | 5 | 2020 | 3580 | 0.180 |
Why?
| | Receptor, IGF Type 1 | 2 | 2010 | 58 | 0.180 |
Why?
| | Air Pollutants | 1 | 2023 | 246 | 0.170 |
Why?
| | Animals | 21 | 2023 | 32102 | 0.170 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2023 | 638 | 0.170 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2020 | 41 | 0.170 |
Why?
| | Cell Cycle Proteins | 2 | 2018 | 553 | 0.170 |
Why?
| | Respiratory System | 1 | 2020 | 141 | 0.170 |
Why?
| | Gene Expression Profiling | 2 | 2005 | 1536 | 0.170 |
Why?
| | Carcinoma in Situ | 1 | 2019 | 44 | 0.170 |
Why?
| | Exons | 1 | 2020 | 300 | 0.160 |
Why?
| | gamma Catenin | 1 | 2018 | 17 | 0.160 |
Why?
| | Fluorescent Antibody Technique | 1 | 2019 | 398 | 0.160 |
Why?
| | Metaplasia | 1 | 2018 | 54 | 0.160 |
Why?
| | MicroRNAs | 2 | 2016 | 607 | 0.160 |
Why?
| | Bronchial Diseases | 1 | 2018 | 38 | 0.160 |
Why?
| | Mucin 5AC | 1 | 2018 | 48 | 0.150 |
Why?
| | Aged, 80 and over | 7 | 2017 | 6417 | 0.150 |
Why?
| | Protein Kinase Inhibitors | 3 | 2023 | 790 | 0.150 |
Why?
| | Cell Cycle Checkpoints | 1 | 2018 | 84 | 0.150 |
Why?
| | Anticarcinogenic Agents | 1 | 2018 | 67 | 0.150 |
Why?
| | Tobacco Smoke Pollution | 1 | 2020 | 221 | 0.150 |
Why?
| | Head and Neck Neoplasms | 1 | 2021 | 425 | 0.150 |
Why?
| | RNA, Messenger | 5 | 2022 | 2574 | 0.150 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 111 | 0.140 |
Why?
| | Urethane | 4 | 2023 | 41 | 0.140 |
Why?
| | Cell Transformation, Viral | 2 | 1993 | 24 | 0.140 |
Why?
| | Myocardial Infarction | 1 | 2003 | 931 | 0.140 |
Why?
| | Antigen Presentation | 1 | 2017 | 189 | 0.140 |
Why?
| | Frizzled Receptors | 1 | 2016 | 23 | 0.140 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 178 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2016 | 67 | 0.130 |
Why?
| | Oncogenes | 1 | 2016 | 104 | 0.130 |
Why?
| | Adult | 11 | 2018 | 30718 | 0.130 |
Why?
| | Porphyrins | 1 | 2015 | 17 | 0.130 |
Why?
| | Tomography, Spiral Computed | 1 | 2015 | 24 | 0.130 |
Why?
| | Topoisomerase Inhibitors | 1 | 2015 | 4 | 0.130 |
Why?
| | Smad4 Protein | 1 | 2015 | 34 | 0.120 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2018 | 396 | 0.120 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2019 | 330 | 0.120 |
Why?
| | Chromosomal Instability | 1 | 2013 | 19 | 0.120 |
Why?
| | Mice, Transgenic | 5 | 2018 | 1970 | 0.110 |
Why?
| | Macrophages, Alveolar | 2 | 2023 | 357 | 0.110 |
Why?
| | Stem Cells | 1 | 2018 | 546 | 0.110 |
Why?
| | Microarray Analysis | 1 | 2013 | 119 | 0.110 |
Why?
| | Neoplasms, Basal Cell | 1 | 2013 | 3 | 0.110 |
Why?
| | Endoscopy | 1 | 2015 | 247 | 0.110 |
Why?
| | Trachea | 1 | 2015 | 233 | 0.110 |
Why?
| | Prognosis | 5 | 2020 | 3339 | 0.110 |
Why?
| | Tretinoin | 1 | 1993 | 124 | 0.110 |
Why?
| | Piperidines | 2 | 2012 | 163 | 0.100 |
Why?
| | Quinazolines | 2 | 2012 | 241 | 0.100 |
Why?
| | B-Lymphocytes | 1 | 2017 | 773 | 0.100 |
Why?
| | Interleukin-1 | 1 | 1996 | 971 | 0.100 |
Why?
| | Cohort Studies | 3 | 2023 | 4944 | 0.100 |
Why?
| | PTEN Phosphohydrolase | 1 | 2013 | 142 | 0.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1361 | 0.100 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2012 | 52 | 0.100 |
Why?
| | Antigens, Differentiation | 1 | 1992 | 79 | 0.100 |
Why?
| | Early Detection of Cancer | 1 | 2015 | 340 | 0.100 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2017 | 965 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 930 | 0.090 |
Why?
| | Cell Line | 4 | 2019 | 2651 | 0.090 |
Why?
| | Hyperplasia | 1 | 2011 | 166 | 0.090 |
Why?
| | Tissue Array Analysis | 3 | 2019 | 49 | 0.090 |
Why?
| | Diagnosis, Differential | 3 | 2021 | 1357 | 0.090 |
Why?
| | Epithelium | 4 | 2018 | 297 | 0.090 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2012 | 225 | 0.090 |
Why?
| | Pulmonary Surgical Procedures | 1 | 2010 | 8 | 0.090 |
Why?
| | Nuclear Proteins | 3 | 2006 | 594 | 0.090 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2010 | 77 | 0.090 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 1098 | 0.080 |
Why?
| | Pulmonary Alveoli | 1 | 2012 | 376 | 0.080 |
Why?
| | Epithelial Cells | 4 | 2018 | 961 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2015 | 4440 | 0.080 |
Why?
| | Cell Polarity | 1 | 2010 | 131 | 0.080 |
Why?
| | Neoplasm Staging | 3 | 2020 | 1178 | 0.080 |
Why?
| | Vasodilator Agents | 1 | 2011 | 308 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2005 | 795 | 0.080 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2008 | 63 | 0.080 |
Why?
| | Solitary Fibrous Tumor, Pleural | 1 | 2008 | 3 | 0.080 |
Why?
| | Osteoarthropathy, Secondary Hypertrophic | 1 | 2008 | 4 | 0.080 |
Why?
| | Echocardiography | 2 | 2003 | 558 | 0.080 |
Why?
| | Smokers | 2 | 2019 | 147 | 0.070 |
Why?
| | Neoplasms, Experimental | 2 | 2018 | 153 | 0.070 |
Why?
| | Carcinoma, Small Cell | 1 | 2008 | 159 | 0.070 |
Why?
| | Fibroblast Growth Factors | 1 | 2008 | 162 | 0.070 |
Why?
| | Genome-Wide Association Study | 1 | 2013 | 1217 | 0.070 |
Why?
| | Edema | 1 | 2008 | 119 | 0.070 |
Why?
| | Monocytes | 1 | 2010 | 507 | 0.070 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2353 | 0.070 |
Why?
| | Radiography, Thoracic | 1 | 2008 | 165 | 0.070 |
Why?
| | Biomarkers | 4 | 2023 | 3466 | 0.070 |
Why?
| | Tumor Microenvironment | 2 | 2021 | 431 | 0.070 |
Why?
| | Treatment Outcome | 5 | 2022 | 9159 | 0.070 |
Why?
| | Minichromosome Maintenance Complex Component 2 | 1 | 2006 | 4 | 0.070 |
Why?
| | Prevalence | 2 | 2023 | 2264 | 0.070 |
Why?
| | Hydrogels | 2 | 2023 | 581 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 1918 | 0.070 |
Why?
| | Placebos | 2 | 2019 | 198 | 0.070 |
Why?
| | Hypoxia | 1 | 2012 | 937 | 0.070 |
Why?
| | Transcription Factors | 1 | 1993 | 1528 | 0.060 |
Why?
| | Mice, Inbred A | 2 | 2020 | 45 | 0.060 |
Why?
| | Chromosome Aberrations | 2 | 2017 | 134 | 0.060 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 2 | 2018 | 228 | 0.060 |
Why?
| | Prospective Studies | 4 | 2023 | 6264 | 0.060 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2005 | 104 | 0.060 |
Why?
| | Bronchoscopy | 2 | 2019 | 245 | 0.060 |
Why?
| | Japan | 1 | 2003 | 88 | 0.060 |
Why?
| | Gene Knockdown Techniques | 2 | 2015 | 302 | 0.050 |
Why?
| | Aniline Compounds | 1 | 2023 | 71 | 0.050 |
Why?
| | Formaldehyde | 1 | 2022 | 47 | 0.050 |
Why?
| | Signal Transduction | 3 | 2012 | 4541 | 0.050 |
Why?
| | Diagnostic Errors | 1 | 2003 | 151 | 0.050 |
Why?
| | Keratin-5 | 1 | 2022 | 46 | 0.050 |
Why?
| | Alveolar Epithelial Cells | 1 | 2023 | 100 | 0.050 |
Why?
| | Up-Regulation | 1 | 2005 | 820 | 0.050 |
Why?
| | Molecular Targeted Therapy | 2 | 2018 | 348 | 0.050 |
Why?
| | Particle Size | 1 | 2023 | 319 | 0.050 |
Why?
| | Immunoenzyme Techniques | 2 | 2012 | 193 | 0.050 |
Why?
| | Mice, Inbred BALB C | 2 | 2011 | 1168 | 0.050 |
Why?
| | Tubulin | 1 | 2022 | 123 | 0.050 |
Why?
| | Double-Blind Method | 2 | 2019 | 1660 | 0.050 |
Why?
| | Adaptive Immunity | 1 | 2023 | 157 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2006 | 1718 | 0.050 |
Why?
| | Interferon-gamma | 2 | 2018 | 726 | 0.050 |
Why?
| | Particulate Matter | 1 | 2023 | 183 | 0.050 |
Why?
| | Incidence | 2 | 2008 | 2335 | 0.050 |
Why?
| | PPAR gamma | 1 | 2022 | 185 | 0.050 |
Why?
| | Pain, Postoperative | 1 | 2022 | 195 | 0.050 |
Why?
| | Exercise Test | 1 | 2003 | 539 | 0.050 |
Why?
| | Acute Disease | 1 | 2003 | 914 | 0.050 |
Why?
| | Electrocardiography | 1 | 2003 | 560 | 0.040 |
Why?
| | Oximes | 1 | 2020 | 19 | 0.040 |
Why?
| | Blotting, Western | 2 | 2012 | 1153 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2011 | 1872 | 0.040 |
Why?
| | Pyrimidinones | 1 | 2020 | 88 | 0.040 |
Why?
| | Environmental Exposure | 1 | 2023 | 378 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2023 | 4773 | 0.040 |
Why?
| | Rituximab | 1 | 2020 | 149 | 0.040 |
Why?
| | Amino Acid Substitution | 1 | 2020 | 267 | 0.040 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2021 | 342 | 0.040 |
Why?
| | RNA | 1 | 2005 | 819 | 0.040 |
Why?
| | Mass Screening | 2 | 2004 | 1024 | 0.040 |
Why?
| | Pyridones | 1 | 2020 | 125 | 0.040 |
Why?
| | Cell Line, Transformed | 2 | 1996 | 133 | 0.040 |
Why?
| | Remission Induction | 1 | 2019 | 240 | 0.040 |
Why?
| | Imidazoles | 1 | 2020 | 217 | 0.040 |
Why?
| | Risk Factors | 3 | 2019 | 8697 | 0.040 |
Why?
| | Diagnostic Imaging | 1 | 2021 | 296 | 0.040 |
Why?
| | Tobacco Smoking | 1 | 2018 | 21 | 0.040 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2018 | 56 | 0.040 |
Why?
| | Tricuspid Valve | 1 | 1998 | 23 | 0.040 |
Why?
| | RNA, Small Interfering | 2 | 2012 | 544 | 0.040 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 192 | 0.040 |
Why?
| | Time | 1 | 2018 | 72 | 0.040 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2018 | 108 | 0.040 |
Why?
| | Ventricular Outflow Obstruction | 1 | 1998 | 37 | 0.040 |
Why?
| | Immunotherapy | 1 | 2021 | 479 | 0.040 |
Why?
| | Tumor Burden | 1 | 2018 | 261 | 0.040 |
Why?
| | Lymphocyte Count | 1 | 2017 | 133 | 0.040 |
Why?
| | DNA Copy Number Variations | 1 | 2018 | 156 | 0.040 |
Why?
| | Carcinogenicity Tests | 1 | 1996 | 5 | 0.040 |
Why?
| | Antigen-Presenting Cells | 1 | 2017 | 153 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2018 | 511 | 0.040 |
Why?
| | Blotting, Northern | 1 | 1996 | 194 | 0.030 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 1996 | 39 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2017 | 277 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2016 | 3914 | 0.030 |
Why?
| | Neoplasms | 1 | 2010 | 2118 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 1996 | 235 | 0.030 |
Why?
| | Centrosome | 1 | 2016 | 59 | 0.030 |
Why?
| | Plasmids | 1 | 1996 | 345 | 0.030 |
Why?
| | Cell Differentiation | 2 | 1993 | 1700 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2019 | 377 | 0.030 |
Why?
| | Mitotic Index | 1 | 2015 | 26 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1219 | 0.030 |
Why?
| | Mice, Nude | 1 | 1996 | 639 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 443 | 0.030 |
Why?
| | Phenotype | 2 | 1993 | 2829 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 244 | 0.030 |
Why?
| | Computational Biology | 1 | 2018 | 536 | 0.030 |
Why?
| | Uterine Cervical Neoplasms | 1 | 1996 | 213 | 0.030 |
Why?
| | Loss of Heterozygosity | 1 | 2013 | 41 | 0.030 |
Why?
| | Retinoid X Receptors | 1 | 1993 | 39 | 0.030 |
Why?
| | Macrophages | 1 | 2020 | 1284 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2017 | 1057 | 0.030 |
Why?
| | Receptors, Retinoic Acid | 1 | 1993 | 50 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2012 | 2751 | 0.030 |
Why?
| | DNA Repair | 1 | 2015 | 190 | 0.030 |
Why?
| | Organ Culture Techniques | 1 | 1993 | 143 | 0.030 |
Why?
| | Models, Molecular | 1 | 2018 | 1390 | 0.030 |
Why?
| | Cytosol | 1 | 1993 | 209 | 0.030 |
Why?
| | Drug Resistance | 1 | 1993 | 162 | 0.030 |
Why?
| | Respiratory Mucosa | 1 | 2015 | 258 | 0.030 |
Why?
| | Methylcholanthrene | 1 | 2012 | 18 | 0.030 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2012 | 43 | 0.030 |
Why?
| | Butylated Hydroxytoluene | 1 | 2012 | 32 | 0.030 |
Why?
| | United States | 2 | 2011 | 12295 | 0.030 |
Why?
| | Immunoprecipitation | 1 | 2012 | 154 | 0.030 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 1992 | 49 | 0.030 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 1993 | 195 | 0.020 |
Why?
| | Intermediate Filament Proteins | 1 | 1992 | 66 | 0.020 |
Why?
| | Gene Deletion | 1 | 2013 | 355 | 0.020 |
Why?
| | Administration, Topical | 1 | 2011 | 137 | 0.020 |
Why?
| | Sleep Apnea Syndromes | 1 | 2012 | 74 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2012 | 114 | 0.020 |
Why?
| | Keratins | 1 | 1992 | 176 | 0.020 |
Why?
| | Mutation, Missense | 1 | 2013 | 296 | 0.020 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 1893 | 0.020 |
Why?
| | Administration, Oral | 1 | 2012 | 734 | 0.020 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2012 | 225 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2578 | 0.020 |
Why?
| | Carcinoma, Large Cell | 1 | 2010 | 14 | 0.020 |
Why?
| | RNA Interference | 1 | 2012 | 438 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 704 | 0.020 |
Why?
| | Cell Division | 1 | 1992 | 759 | 0.020 |
Why?
| | Aneuploidy | 1 | 2010 | 86 | 0.020 |
Why?
| | Mice, Inbred Strains | 1 | 2010 | 399 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2010 | 209 | 0.020 |
Why?
| | Antioxidants | 1 | 2012 | 533 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2010 | 621 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 4435 | 0.020 |
Why?
| | Cell Movement | 1 | 2012 | 867 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2010 | 815 | 0.020 |
Why?
| | Survival Rate | 1 | 2011 | 1650 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2010 | 608 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2010 | 1087 | 0.020 |
Why?
| | Skin | 1 | 1991 | 662 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2010 | 1870 | 0.020 |
Why?
| | Databases, Nucleic Acid | 1 | 2005 | 33 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2012 | 3022 | 0.020 |
Why?
| | Enzymes | 1 | 2005 | 61 | 0.020 |
Why?
| | Cytokines | 1 | 2012 | 1853 | 0.010 |
Why?
| | Species Specificity | 1 | 2005 | 552 | 0.010 |
Why?
| | DNA Replication | 1 | 2005 | 203 | 0.010 |
Why?
| | Cluster Analysis | 1 | 2005 | 465 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 1265 | 0.010 |
Why?
| | Age Factors | 1 | 2011 | 2907 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2005 | 746 | 0.010 |
Why?
| | Apoptosis | 1 | 2012 | 2377 | 0.010 |
Why?
| | Young Adult | 1 | 2018 | 10470 | 0.010 |
Why?
| | Risk Assessment | 1 | 2010 | 2987 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2016 | 12608 | 0.010 |
Why?
| | Time Factors | 1 | 2010 | 6165 | 0.010 |
Why?
| | Echocardiography, Transesophageal | 1 | 1998 | 89 | 0.010 |
Why?
| | Culture Techniques | 1 | 1991 | 80 | 0.010 |
Why?
| | Reference Values | 1 | 1991 | 744 | 0.010 |
Why?
|
|
Merrick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|